Aryeh Jason sold 282 shares of LIGAND PHARMACEUTICALS INC at $319.99 for −$90.2k on Nov 4, 2026

Sell
Form 4 code S. Open-market or private sale of a non-derivative or derivative security.
Director
DIR
Filed Nov 6, 2026

Facts from the filing

Form 4 · Non-derivative, table I
Disclosed value
−$90,237.18Shares × reported price
Shares traded
282Common Stock
Price per share
$319.99Reported price. Read footnotes for ranges.
% of reported position traded
0.26%This security and ownership context
Holdings after
108,476Direct
Trade date
Nov 4, 2026Sell
Filed
Nov 6, 2026, 5:41 PM ET2-day reporting delay
Accession
0001376960-26-000006Code S · Transaction 395254
How reported position traded is calculated

Shares sold ÷ (holdings after + shares sold). Estimated position before: 108,758 shares.

Row-level estimate for this security and ownership context, not the insider’s complete portfolio. Joint ownership, other transactions in the filing, amendments and footnotes can affect interpretation.

Other trades in this filing

No other transaction rows in this filing.

1 transaction row in this filing. Joint filers share the same rows.

LGND price since this filing

Daily closing prices, with the filing date and available return windows. Return methodology
LGND · Daily closing priceDaily price data is pending. The chart appears when valid daily closes are available.
Filing dateReturn windows appear as prices become available.
Pre-filing1mo ago +0.2%1w ago +4.1%1d ago +2.4%
Returns since7d +0.8%30d90d180d1y

Footnotes in full

F1: These shares are held by certain funds managed by JALAA Equities, LP, JLV Investments, LP and affiliates (the Funds). Jason Aryeh is the General Partner of JALAA Equities, LP and a partner of JLV Investments, LP. By reason of the provisions of Rule 16a-1 under the Securities Exchange Act of 1934, as amended, JALAA Equities, LP, JLV Investments, LP and affiliates and Mr. Aryeh may be deemed to be the beneficial owners of the securities beneficially owned by the Funds.